Upper gastrointestinal Crohn's disease

Détails

ID Serval
serval:BIB_5E8AE3C897E8
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Institution
Titre
Upper gastrointestinal Crohn's disease
Périodique
Digestion
Auteur(s)
Mottet  Christian, Juillerat  Pascal, Pittet  Valérie, Gonvers  Jean-Jacques, Michetti  Pierre, Vader  John-Paul, Felley  Christian, Froehlich  Florian
ISSN
0012-2823
Statut éditorial
Publié
Date de publication
2007
Peer-reviewed
Oui
Volume
76
Numéro
2
Pages
136-140
Notes
SAPHIRID:64229
Résumé
Symptomatic gastroduodenal manifestations of Crohn's disease are rare, with less than 4% of patients being clinically symptomatic. Gastroduodenal involvement may, however, be found endoscopically in 20% and in up to 40% of cases histologically, most frequently as Helicobacter pylori-negative focal gastritis, usually in patients with concomitant distal ileal disease. In practice, the activity of concomitant distal Crohn's disease usually determines the indication for therapy, except in the presence of obstructive gastroduodenal symptoms. With the few data available, it seems correct to say that localized gastroduodenal disease should be treated with standard medical therapy used for more distal disease, with the exception of the galenic formulation of sulfasalazine and mesalazine with pH-dependent release. The presence of symptoms of obstruction needs aggressive therapy. If medical therapy with steroids and immunomodulatory drugs does not alleviate the symptoms, balloon dilation and surgery are the options to consider. [Ed.]
Pubmed
Web of science
Création de la notice
03/03/2008 11:52
Dernière modification de la notice
20/08/2019 15:16
Données d'usage